The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 2212-6988|4|1|47-58

ISSN： 2212-697x

Source： Clinical Cancer Drugs, Vol.4, Iss.1, 2017-05, pp. : 47-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation

By  

Current Pharmaceutical Design, Vol. 23, Iss. 11, 2017-05 ,pp. : 1633-1638

Bentham Science Publishers

Access to resources Recommend Favorite

The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer

By  

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 9, 2015-01 ,pp. : 804-815

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

By  

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite